Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.

Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.

Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.

Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.

Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.

Abstract: The present invention relates to the novel finding that inhibition of human CARP protein or of CARP DNA/mRNA may successfully cure heart disorders, especially heart failure in humans. The invention relates, therefore, to pharmaceutical compositions containing substances, preferably of lower molecular weight, which may influence the activity of cardiac CARP. The invention relates, furthermore, to a method of treatment heart failure using CARP inhibitory compounds, to methods for screening these inhibitors and to the use of CARP as diagnostic tool.

Abstract: Nkx2-C4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Nkx2-C4 polypeptides and polynucleotides in diagnostic assays.

Abstract: RGS8 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing RGS8 polypeptides and polynucleotides in diagnostic assays.

Abstract: The invention relates to compounds of the formula (I): in which (Y) is formula (I) or formula (III) and Het, R1, R2, R5, R6, R7 and R8 are as defined above, and salts and solvates thereof, and to the use thereof as NHE-3 inhibitors.

Abstract: The invention relates to the use of type 4 phosphodiesterase inhibitors to treat myocardial diseases.

Abstract: The invention relates to compounds of formula (I), where Ar=unsubstituted, or monosubstituted by R3, phenyl, or naphthyl; R1, R2=independently, A, OA, Hal or CF3; R3=A, OA, Hal, or CF3; A=1-6C alkyl and Hal=F, Cl, Br or I and the salts and solvates thereof as NHE3 inhibitors.

Abstract: Nkx2-C4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Nkx2-C4 polypeptides and polynucleotides in diagnostic assays.

Abstract: Calcineurin B subunit beta polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing calcineurin B subunit beta polypeptides and polynucleotides in diagnostic assays.

Abstract: The invention relates to compounds of the formula I, in which Y is (II) or (III) and Ar, R1, R2, R5, R6, R7 and R8 are as defined above, and their salts and solvates, and to their use as NHE-3 inhibitors.

Abstract: The present invention relates to the novel finding that inhibition of human CARP protein or of CARP DNA/mRNA may successfully cure heart disorders, especially heart failure in humans. The invention relates, therefore, to pharmaceutical compositions containing substances, preferably of lower molecular weight, which may influence the activity of cardiac CARP. The invention relates, furthermore, to a method of treatment heart failure using CARP inhibitory compounds, to methods for screening these inhibitors and to the use of CARP as diagnostic tool.

Abstract: RGS8 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing RGS8 polypeptides and polynucleotides in diagnostic assays.

Abstract: HNCX3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNCX3 polypeptides and polynucleotides in diagnostic assays.

Abstract: The invention relates to the use of a highly penis-specific PDE V inhibitor, or a physiologically acceptable salt or solvate thereof, for the production of a medicament for the treatment of erectile dysfunction in males, without the previous circulatory side effects caused by PDE V inhibitors, in particular, with concomitant administration of vasodilators, whose mode of action is by means of the NO/cGMP system.

Abstract: Novel compounds of the formula I in which R is X is O or S, and R1, R2, R3, R4, R5 and R6 have the meaning indicated in patent claim 1, or a tautomeric ring-closed form, and the (E) isomers and their salts exhibit endothelin receptor-antagonistic properties.

Abstract: The invention concerns compounds of formula (I),in which R is (i), (ii) or (iii); n is 0, 1 or 2; X means O or S; and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have different meanings, or a cyclized tautomeric shape. The invention also concerns the (E) isomers and salts of these compounds which display endothelin receptor antagonistic properties.